The clinical efficacy and safety of Ganluxiaodu micropills in treatment of Hp infected chronic atrophic gastritis / 中国基层医药

ABSTRACT

Objective To investigate the clinical efficacy and safety of Ganluxiaodu micropills in treatment of helicobacter pylori(Hp)infected chronic atrophic gastritis.Methods 120 patients with chronic atrophic gastritis (pixu shire syndrome)from April 2013 to April 2014 were selected and divided into observation group and the control group (n =60)according to random number table method.The control group was given standard triple therapy,the observation group was given Ganluxiaodu micropills on the basis of the control group,7 days for a period of treatment. The symptoms changes of the two groups before and after treatment were observed and combined results of the gastro-scope and breath test,determined the clinical curative effect and eradication rate of Hp.The SF -36 scale score was used to evaluate the quality of life of the patients.Results The clinical symptom scores[(15.92 ±2.25)points vs (16.12 ±2.14)points ],SF -36 scale [(68.05 ±12.98)points vs (65.77 ±11.34)points]of the two groups before treatment had no statistically significant differences (t =-1.033,-1.239,all P >0.05).The clinical symp-tom scores and SF -36 score of the observation group and the control group after treatment [(8.24 ±1.23)points, (89.44 ±12.93)points;(12.65 ±1.75)points,(77.43 ±11.59)points ]were obviously improved than before treat-ment,the differences were statistically significant (t =2.574,2.765,2.133,2.047,all P 0.05).Conclusion Ganluxiaodu micropills can improve the Hp eradicate rate of standard triple therapy,the clinical efficacy of Ganluxiaodu micropills in treatment of Hp infected chronic atrophic gastritis (pixu shire syndrome)is significant,which is worthy of clinical popularization and application.